We next evaluated whether FZD6 knockdown enhances the therapeutic effect of cisplatin toward advanced human prostate cancers in vivo using the LuCaP35CR CRPC model that we have engineered to express the doxycycline inducible FZD6 shRNA. The gene discussed is FZD6; the disease is prostate cancer.